China Vs. Cancer: Seven Companies Given Price Cuts, Roche Gets New Approval
Executive Summary
Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.
You may also be interested in...
Winner Takes All: New China Bidding Scheme Marks Price Watershed?
With tens of millions of dollars in sales at stake, a number of mostly commonly used drugs are subject to the first-ever nationwide drug price bidding process in China, with foreign firms seeing the move as opening the floodgate to a potential downward price spiral in the world’s second-largest pharma market.
Biosimilar Tipping Point: Five Questions For Henlius CEO
Now valued at close to $3bn, Henlius is one of the largest biotech unicorns in China. CEO Scott Liu sat down with Scrip in an exclusive interview to discuss biosimilar development in China, emerging market expansion plans, and its venture into immuno-oncology combo strategy.
Biosimilar Tipping Point: Five Questions For Henlius CEO
Now valued at close to $3bn, Henlius is one of the largest biotech unicorns in China. CEO Scott Liu sat down with Scrip in an exclusive interview to discuss biosimilar development in China, emerging market expansion plans, and its venture into immuno-oncology combo strategy.